Advertisement
Advertisement
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
As of 09:35AM EDT. Market open.
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.2644 |
| Open | 0.2700 |
| Bid | 0.2600 x 1800 |
| Ask | 0.2650 x 1000 |
| Day's Range | 0.2638 - 0.2722 |
| 52 Week Range | 0.2080 - 1.3200 |
| Volume | |
| Avg. Volume | 1,278,001 |
| Market Cap | 34.088M |
| Beta (5Y Monthly) | 2.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3870 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.98 |
- Zacks
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -16.67% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.
- PR Newswire
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that new preclinical data for CRB-601 are being presented today in an oral presentation at the New York Academy of Sciences (NYAS) Frontiers in Cancer Immunotherapy Conference in New York, NY.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
